More good news, this time from the Oxford vaccine. The trials are at an earlier stage (phase 2/3) so there are no efficacy numbers yet, but these data show a good immune response, and similar across all age groups including the elderly participants.
This is an adenovirus-vectored vaccine. It uses the same antigen, the Spike protein, and its manner of action is somewhat similar to the mRNA vaccines. Rather than injecting the antigen itself, the engineered adenovirus vector enters your cells and causes your own cells to make the Spike protein, triggering the immune response. But unlike the mRNA vaccines, adenovirus is DNA, so the DNA > mRNA > protein production process all takes place inside your cell, rather than injecting mRNA directly.